Abu-Raya, BahaaMaertens, KirstenMunoz, Flor MZimmermann, PetraCurtis, NigelHalperin, Scott ARots, NynkeBarug, DaanHolder, BethKampmann, BeateLeuridan, ElkeSadarangani, Manish2021-08-022021-08-022021-07-063430592210.3389/fimmu.2021.689394http://hdl.handle.net/10029/625201Infants of Tdap-immunized women had significantly lower IgG against pertussis toxin (GMR 0.65; 95%CI 0.57-0.74), filamentous haemagglutinin (FHA) (0.68; 0.53-0.87), pertactin (0.65; 0.58-0.72) and fimbria 2/3 (FIM2/3) (0.41; 0.32-0.52) after primary immunization, compared with infants of unimmunized women. These lower levels persisted after booster immunization for FHA (0.72; 0.61-0.84) and FIM2/3 (0.53; 0.29-0.96). After primary immunization, infants of Tdap-immunized women had lower seroprotection rates against diphtheria (90% [843/973] vs 98% [566/579]; p<0.001) and invasive pneumococcal disease (IPD) caused by 5 Streptococcus pneumoniae (SPN) serotypes (SPN5, SPN6B, SPN9V, SPN19A, SPN23F), and higher seroprotection rates against Haemophilus influenzae type b (short-term and long-term seroprotection rates, 86%[471/547] vs 76%[188/247] and 62%[337/547] vs 49%(121/247), respectively, all p=0.001). After booster immunization, seroprotection rates against diphtheria and tetanus were 99% (286/288) and (618/619) in infants of Tdap-immunized women, respectively.enCopyright © 2021 Abu-Raya, Maertens, Munoz, Zimmermann, Curtis, Halperin, Rots, Barug, Holder, Kampmann, Leuridan and Sadarangani.gestationalimmunizationinfantspertussispregnancyArticle1664-3224Front Immunol 2021; 12:689394